A Phase 3 interventional study of Remdesivir and Tocilizumab in COVID-19 Pneumonia, sponsored by Hoffmann-La Roche. Completed at 54 sites in 4 countries. Open to participants aged 12 Years and older. Per ClinicalTrials.gov, last updated 2022-02-14.
Sponsored by Hoffmann-La Roche · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 38 studies testing tocilizumab in COVID-19 — 3 open to participants now, 4 under way, 2 of them phase 3. tocilizumab · COVID-19.
Among the 38 studies testing tocilizumab in COVID-19, this one is the 5th largest by enrollment, is one of 34 that started in 2020, is one of 13 in phase 3, and was the 22nd registered.
7,994 studies on the registry are indexed under COVID-19; 467 are open to participants now.
Browse COVID-19 studies →3 of the 38 studies testing tocilizumab in COVID-19 are open now, in 12 countries. Recruiting first, the newest first:
Lebanese University · Sites in Lebanon
Ages 18+
University of Oxford · Sites in Belgium, Estonia, France and 13 more countries
Ages 0+
UMC Utrecht · Sites in United States, Australia, Belgium and 26 more countries
Ages 28 days+
By country, each count listing its studies:
tocilizumab: first FDA approval 2010 (ACTEMRA), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 356 COVID-19 studies recruiting now, 206 (58%) set no upper age limit and 83 (23%) stop at 75 or younger; 91 take children under 18; 135 take healthy volunteers.
This study: 12 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
38 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 3 · Phase 2 15 · Phase 3 14 · Phase 4 2
First in 2016; this study’s year is marked. 34 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 649 is above the median of 102 across 4,366 interventional studies indexed under COVID-19.
Median enrollment 150 across the 38 interventional studies. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
5 of 38 have an industry lead sponsor. The 10 most frequent:
Hoffmann-La Roche is the lead sponsor of 2,102 studies on the registry; 89 are open to participants now.
Of its 330 completed or terminated interventional studies of FDA-regulated products, 248 (75%) have results posted.
Hoffmann-La Roche has 9 studies filed under COVID-19 — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 38 studies testing tocilizumab in COVID-19, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study will evaluate the efficacy and safety of combination therapy with remdesivir plus tocilizumab compared with remdesivir plus placebo in hospitalized patients with COVID-19 pneumonia.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants assigned to the RDV+TCZ arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ on Day 1.
Drug: Remdesivir · Drug: Tocilizumab
Participants assigned to the RDV+ placebo arm will receive a 10-day treatment course of RDV, plus one infusion of TCZ-placebo on Day 1.
Drug: Remdesivir · Drug: Placebo
Participants will receive intravenous (IV) RDV
Participants will receive IV TCZ
Participants will receive IV placebo matched to TCZ
Time to Hospital Discharge or "Ready for Discharge" up to Day 28
Defined as days from randomization to hospital discharge or "Ready for Discharge" not followed by ordinal scale category \>1, hospital readmission or death. Hospital discharge or "Ready for Discharge" is defined as an ordinal score of 1 on the 7-point ordinal scale. Participants who die are censored at Day 28. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
Time frame: Up to Day 28
Time to Mechanical Ventilation or Death up to Day 28
Time to Mechanical Ventilation or Death defined as the time from randomization to the first occurrence of death or mechanical ventilation. For participants already on mechanical ventilation at baseline, only death is counted as an event.
Time frame: Up to Day 28
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 14
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
Time frame: Day 14
Time to Death up to Day 28
Time to death is defined as the time from randomization to death.
Time frame: Up to Day 28
Time to Death up to Day 60
Time to death is defined as the time from randomization to death.
Time frame: Up to Day 60
Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-category Ordinal Scale of Clinical Status up to Day 28
Defined as time from randomization to the time when at least a 2-category improvement in the 7-category ordinal scale is observed. Patients who die are censored at day 28. Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
Time frame: Up to Day 28
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 7
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
Time frame: Day 7
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 21
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
Time frame: Day 21
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 28
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
Time frame: Day 28
Clinical Status as Assessed by the Investigator Using a 7-category Ordinal Scale of Clinical Status on Day 60
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
Time frame: Day 60
Proportion of Participants Requiring Initiation of Mechanical Ventilation Post-baseline (Participants Who Did Not Require Mechanical Ventilation at Baseline)
Day 28: Participants who withdraw or die prior to Day 28 are assumed to have required mechanical ventilation. Participants without mechanical ventilation prior to discharge are assumed not to have required mechanical ventilation unless they die by Day 28, which are counted as an event. Day 60: Participants who withdraw or die prior to Day 60 are assumed to have required mechanical ventilation. Participants without mechanical ventilation prior to discharge are assumed not to have required mechanical ventilation unless they die by Day 60, which are counted as an event.
Time frame: Day 28 and Day 60
Proportion of Participants Who Are Alive and Free of Respiratory Failure at Day 28 and Day 60 (Participants Requiring Mechanical Ventilation at Baseline)
Time frame: Day 28 and Day 60
Duration of Mechanical Ventilation (Participants Requiring Mechanical Ventilation at Baseline) up to Day 28
Participants who die by Day 28 are assigned a duration of 28 days.
Time frame: Up to Day 28
Difference in Mortality at Days 14, 28, and 60
Time frame: Days 14, 28, and 60
Time to Recovery up to Day 28
Defined as the time from randomization to the time when an ordinal scale category of 2 (non-ICU hospital ward or "ready for hospital ward" not requiring supplemental oxygen) or better is observed, not followed by ordinal scale category \>2 or death. Participants who die are censored at day 28. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
Time frame: Up to Day 28
Proportion of Participants Who Are Discharged or "Ready for Discharge" up to Day 28
Defined as hospital discharge or "Ready for Discharge" not followed by ordinal scale category \>1, hospital readmission or death. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
Time frame: Up to Day 28
Proportion of Participants Who Require Initiation of Mechanical Ventilation Post-baseline or Die up to Day 28
Participants already on mechanical ventilation at baseline are only counted as an event if death occurs.
Time frame: Up to Day 28
Percentage of Participants With Adverse Events (AEs) Tabulated by Severity
AEs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death related to AE Participants are counted at the highest AE grade experienced.
Time frame: Up to Day 60
Proportion of Participants With Any Post-Treatment Infection
Time frame: Up to Day 60
Participants with severe COVID-19 pneumonia
| Milestone | Remdesivir + Placebo (RDV+PBO) | Remdesivir + Tocilizumab (RDV+TCZ) |
|---|---|---|
| Started | 215 | 434 |
| Completed | 140 | 300 |
| Not completed | 75 | 134 |
| Withdrew: Adverse event | 0 | 2 |
| Withdrew: Death | 55 | 97 |
| Withdrew: Lost to follow-up | 12 | 23 |
| Withdrew: Lack of staff | 0 | 1 |
| Withdrew: Protocol violation | 3 | 1 |
| Withdrew: Withdrawal by subject | 5 | 10 |
Defined as days from randomization to hospital discharge or "Ready for Discharge" not followed by ordinal scale category \>1, hospital readmission or death. Hospital discharge or "Ready for Discharge" is defined as an ordinal score of 1 on the 7-point ordinal scale. Participants who die are censored at Day 28. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
| days | Remdesivir + Placebo (RDV+Placebo) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Time to Hospital Discharge or "Ready for Discharge" up to Day 28 | 14.0 (11.0 to 16.0) | 14.0 (12.0 to 15.0) |
Time to Mechanical Ventilation or Death defined as the time from randomization to the first occurrence of death or mechanical ventilation. For participants already on mechanical ventilation at baseline, only death is counted as an event.
| Days | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Time to Mechanical Ventilation or Death up to Day 28 | NA (NA to NA) | NA (NA to NA) |
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
| Percentage of Participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Category 1 | 52.4 | 54.0 |
| Category 2 | 1.9 | 2.6 |
| Category 3 | 11.4 | 8.9 |
| Category 4 | 6.7 | 9.6 |
| Category 5 | 6.7 | 4.9 |
| Category 6 | 11.4 | 10.0 |
| Category 7 | 9.5 | 10.0 |
Time to death is defined as the time from randomization to death.
| Days | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Time to Death up to Day 28 | NA (NA to NA) | NA (NA to NA) |
Time to death is defined as the time from randomization to death.
| Days | Remdesivir + Placebo (RDV+Placebo) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Time to Death up to Day 60 | NA (NA to NA) | NA (NA to NA) |
Defined as time from randomization to the time when at least a 2-category improvement in the 7-category ordinal scale is observed. Patients who die are censored at day 28. Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
| Days | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Time to Improvement of at Least 2 Categories Relative to Baseline on a 7-category Ordinal Scale of Clinical Status up to Day 28 | 11.0 (10.0 to 13.0) | 12.0 (11.0 to 13.0) |
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
| Percentage of participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Category 1 | 21.9 | 19.4 |
| Category 2 | 4.3 | 5.6 |
| Category 3 | 17.6 | 20.1 |
| Category 4 | 30.0 | 29.4 |
| Category 5 | 9.5 | 10.0 |
| Category 6 | 12.9 | 12.1 |
| Category 7 | 3.8 | 3.3 |
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
| Percentage of Participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Category 1 | 62.4 | 64.3 |
| Category 2 | 1.4 | 1.2 |
| Category 3 | 4.8 | 4.7 |
| Category 4 | 2.9 | 4.4 |
| Category 5 | 6.7 | 5.6 |
| Category 6 | 7.1 | 5.8 |
| Category 7 | 14.8 | 14.0 |
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
| Percentage of Participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Category 1 | 67.1 | 66.4 |
| Category 2 | 1.4 | 1.4 |
| Category 3 | 1.0 | 3.5 |
| Category 4 | 2.9 | 3.0 |
| Category 5 | 4.3 | 3.7 |
| Category 6 | 3.8 | 3.7 |
| Category 7 | 19.5 | 18.2 |
Clinical status was assessed by the investigator according to the following ordinal scale categories: 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
| Percentage of Participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Category 1 | 70.0 | 72.2 |
| Category 2 | 1.4 | 0.7 |
| Category 3 | 1.0 | 1.4 |
| Category 4 | 1.4 | 1.6 |
| Category 5 | 0.5 | 0.7 |
| Category 6 | 0 | 0.7 |
| Category 7 | 25.7 | 22.7 |
Day 28: Participants who withdraw or die prior to Day 28 are assumed to have required mechanical ventilation. Participants without mechanical ventilation prior to discharge are assumed not to have required mechanical ventilation unless they die by Day 28, which are counted as an event. Day 60: Participants who withdraw or die prior to Day 60 are assumed to have required mechanical ventilation. Participants without mechanical ventilation prior to discharge are assumed not to have required mechanical ventilation unless they die by Day 60, which are counted as an event.
| Percentage of Participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Day 28 | 29.8 (23.3 to 36.3) | 27.5 (23.0 to 32.0) |
| Day 60 | 31.4 (24.7 to 38.0) | 28.8 (24.2 to 33.5) |
| Percentage of Participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Day 28 | 54.5 (33.7 to 75.4) | 40.7 (28.1 to 53.2) |
| Day 60 | 63.6 (43.5 to 83.7) | 47.5 (34.7 to 60.2) |
Participants who die by Day 28 are assigned a duration of 28 days.
| Days | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Duration of Mechanical Ventilation (Participants Requiring Mechanical Ventilation at Baseline) up to Day 28 | 16.7 (11.9 to 21.5) | 19.6 (16.8 to 22.4) |
| Percentage of Participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Day 14 | 9.5 (5.6 to 13.5) | 10.0 (7.2 to 12.8) |
| Day 28 | 19.5 (14.2 to 24.9) | 18.1 (14.5 to 21.8) |
| Day 60 | 25.7 (19.8 to 31.6) | 22.6 (18.6 to 26.5) |
Defined as the time from randomization to the time when an ordinal scale category of 2 (non-ICU hospital ward or "ready for hospital ward" not requiring supplemental oxygen) or better is observed, not followed by ordinal scale category \>2 or death. Participants who die are censored at day 28. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
| Days | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Time to Recovery up to Day 28 | 13.0 (10.0 to 15.0) | 13.0 (11.0 to 14.0) |
Defined as hospital discharge or "Ready for Discharge" not followed by ordinal scale category \>1, hospital readmission or death. 1. Discharged (or "ready for discharge" as evidenced by normal temperature and respiratory rate, and stable oxygen saturation on ambient air or \</= 2L supplemental oxygen) 2. Non-intensive care unit (ICU) hospital ward (or "ready for hospital ward") not requiring supplemental oxygen 3. Non-ICU hospital ward (or "ready for hospital ward") requiring supplemental oxygen 4. ICU or non-ICU hospital ward, requiring non-invasive ventilation or high-flow oxygen 5. ICU, requiring intubation and mechanical ventilation 6. ICU, requiring extracorporeal membrane oxygenation (ECMO) or mechanical ventilation and additional organ support (e.g., vasopressors, renal replacement therapy) 7. Death
| Percentage of participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Proportion of Participants Who Are Discharged or "Ready for Discharge" up to Day 28 | 67.1 (60.8 to 73.5) | 66.0 (61.6 to 70.5) |
Participants already on mechanical ventilation at baseline are only counted as an event if death occurs.
| Percentage of participants | Remdesivir + Placebo (RDV+PBO) - mITT Population | Remdesivir + Tocilizumab (RDV+TCZ) - mITT Population |
|---|---|---|
| Proportion of Participants Who Require Initiation of Mechanical Ventilation Post-baseline or Die up to Day 28 | 29.0 (22.9 to 35.2) | 28.6 (24.3 to 32.9) |
AEs were reported according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE). Grade 1: Mild; asymptomatic or mild symptoms; clinical or diagnostic observations only; intervention not indicated Grade 2: Moderate; minimal, local or noninvasive intervention indicated; limiting age-appropriate instrumental activities of daily living (ADL) Grade 3: Severe or medically significant but not immediately life-threatening; hospitalization or prolongation of hospitalization indicated; disabling; limiting self care ADL Grade 4: Life-threatening consequences; urgent intervention indicated Grade 5: Death related to AE Participants are counted at the highest AE grade experienced.
| Percentage of participants | Remdesivir + Placebo (RDV+PBO) - Safety Population | Remdesivir + Tocilizumab (RDV+TCZ) - Safety Population |
|---|---|---|
| Grade 1 | 9.9 | 10.5 |
| Grade 2 | 21.1 | 28.2 |
| Grade 3 | 10.3 | 11.2 |
| Grade 4 | 4.2 | 4.9 |
| Grade 5 | 25.8 | 22.6 |
| Percentage of Participants | Remdesivir + Placebo (RDV+PBO) - Safety Population | Remdesivir + Tocilizumab (RDV+TCZ) - Safety Population |
|---|---|---|
| Serious infections | 27.7 | 22.6 |
| Infections | 35.7 | 33.3 |
| Opportunistic infections | 2.3 | 1.4 |
Collected over Up to Day 60. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Remdesivir + Placebo (RDV+PBO) | 55/213 (25.8%) | 76/213 (35.7%) | 70/213 (32.9%) |
| Remdesivir + Tocilizumab (RDV+TCZ) | 97/429 (22.6%) | 141/429 (32.9%) | 144/429 (33.6%) |
| Event | Remdesivir + Placebo (RDV+PBO) | Remdesivir + Tocilizumab (RDV+TCZ) |
|---|---|---|
| COVID-19 pneumoniaInfections and infestations | 27/213 | 36/429 |
| Acute kidney injuryRenal and urinary disorders | 14/213 | 21/429 |
| Septic shockInfections and infestations | 10/213 | 23/429 |
| PneumoniaInfections and infestations | 6/213 | 21/429 |
| COVID-19Infections and infestations | 8/213 | 14/429 |
| SepsisInfections and infestations | 6/213 | 11/429 |
| Renal impairmentRenal and urinary disorders | 5/213 | 1/429 |
| Pneumonia bacterialInfections and infestations | 4/213 | 5/429 |
| HypotensionVascular disorders | 4/213 | 4/429 |
| PneumothoraxRespiratory, thoracic and mediastinal disorders | 1/213 | 7/429 |
| Event | Remdesivir + Placebo (RDV+PBO) | Remdesivir + Tocilizumab (RDV+TCZ) |
|---|---|---|
| ConstipationGastrointestinal disorders | 25/213 | 54/429 |
| AnaemiaBlood and lymphatic system disorders | 14/213 | 13/429 |
| Transaminases increasedInvestigations | 10/213 | 25/429 |
| HypotensionVascular disorders | 12/213 | 19/429 |
| Acute kidney injuryRenal and urinary disorders | 11/213 | 24/429 |
| HypokalaemiaMetabolism and nutrition disorders | 6/213 | 23/429 |
| Urinary tract infectionInfections and infestations | 11/213 | 20/429 |
| HyperglycaemiaMetabolism and nutrition disorders | 9/213 | 22/429 |
| Age, Continuous(Years) | Remdesivir + Placebo (RDV+PBO) | Remdesivir + Tocilizumab (RDV+TCZ) | Total |
|---|---|---|---|
| Mean | 58.2 ± 13.6 | 60.1 ± 13.3 | 59.5 ± 13.4 |
| Sex: Female, Male(Participants) | Remdesivir + Placebo (RDV+PBO) | Remdesivir + Tocilizumab (RDV+TCZ) | Total |
|---|---|---|---|
| Female | 73 | 167 | 240 |
| Male | 142 | 267 | 409 |
| Ethnicity (NIH/OMB)(Participants) | Remdesivir + Placebo (RDV+PBO) | Remdesivir + Tocilizumab (RDV+TCZ) | Total |
|---|---|---|---|
| Hispanic or Latino | 125 | 209 | 334 |
| Not Hispanic or Latino | 88 | 208 | 296 |
| Unknown or Not Reported | 2 | 17 | 19 |
| Race (NIH/OMB)(Participants) | Remdesivir + Placebo (RDV+PBO) | Remdesivir + Tocilizumab (RDV+TCZ) | Total |
|---|---|---|---|
| American Indian or Alaska Native | 4 | 4 | 8 |
| Asian | 5 | 17 | 22 |
| Native Hawaiian or Other Pacific Islander | 3 | 7 | 10 |
| Black or African American | 20 | 52 | 72 |
| White | 154 | 282 | 436 |
| More than one race | 2 | 9 | 11 |
| Unknown or Not Reported | 27 | 63 | 90 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Qualified researchers may request access to individual patient level data through the clinical study data request platform (www.vivli.org). Further details on Roche's criteria for eligible studies are available here (https://vivli.org/ourmember/roche/). For further details on Roche's Global Policy on the Sharing of Clinical Information and how to request access to related clinical study documents, see here (https://www.roche.com/research_and_development/who_we_are_how_we_work/clinical_trials/our_commitment_to_data_sharing.htm).
Ran from Jun 2020 to primary completion in Feb 2021, 7 months.
Results were first posted in Feb 2022, 1 year after primary completion.
Of 168 industry-sponsored phase 3 interventional studies under COVID-19, half reached primary completion within 8 months of starting (the median), counting those still running; a quarter within 4 and three quarters within 16. This study's 7 months is below that.
Counting every sponsor, half of 453 studies reached it within 9 months; a quarter within 4 and three quarters within 17.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jan 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Tocilizumab